Imatinib Combined with Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation versus Imatinib Alone for Chronic Myeloid Leukemia in Chronic Phase

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-12002956

Enrollment

Unknown

Registered

2012-12-31

Start date

2004-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia

Interventions

imatinib combined with reduced-intensity allogenei:imatinib combined with reduced-intensity allogenei

imatinib:imatinib alone

Eligibility

Sex/Gender

All

Age

12 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. gave informed consent; 2. age less than 45 years; 3. diagnosed with CML, as confirmed by the presence of the Philadelphia (Ph) chromosome or the BCR-ABL fusion gene; 4. chronic phase

Exclusion criteria

Exclusion criteria: 1. severe irreversible comorbidity, such as renal, hepatic, pulmonary, or cardiac disease; 2. active infection; 3. pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
overall survival;progression-free survival;	—

Countries

China

Contacts

Public ContactHe Huang

hehuangyu@126.com+86 13605714822

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026